Nathan D Seligson

Nathan D Seligson, Pharm.D.

Clinical Assistant Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (904) 244-9590
Business Email:

About Nathan D Seligson

Dr. Seligson earned his Doctor of Pharmacy degree from the University of South Florida in 2015 prior to completing a pharmacy practice residency in 2016. Dr. Seligson then completed a post-doctoral fellowship in translational hematology/oncology focused on precision medicine in sarcoma.

Dr. Seligson is now a Clinical Assistant Professor in the Department of Pharmacotherapy and Translational Research. His clinical practice includes activities as a clinical pharmacogenomics specialist and hematology/oncology research scientist at Nemours Children’s Specialty Care in Jacksonville, Florida.

Dr. Seligson has been published in as first author in leading journals including: JAMA Open Network, The Oncologist, and Oncotarget. His current research includes work to better understand cancer biology and tumor evolution in order to provide actionable molecular subtyping and pharmacogenomic therapy guidance in sarcoma.


Adding the second T: Elevating STAR to START for behavioral interviewing.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 78(1):18-21 [DOI] 10.1093/ajhp/zxaa356. [PMID] 33155021.
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer.
The Annals of pharmacotherapy. [DOI] 10.1177/1060028020966548. [PMID] 33070624.
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.
Journal of the American Medical Informatics Association : JAMIA. 27(11):1808-1812 [DOI] 10.1093/jamia/ocaa159. [PMID] 32885823.
Integration of EMT and cellular survival instincts in reprogramming of programmed cell death to anastasis.
Cancer metastasis reviews. 39(2):553-566 [DOI] 10.1007/s10555-020-09866-x. [PMID] 32020420.
Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.1946. [PMID] 32535906.
Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.
Cell death discovery. 6 [DOI] 10.1038/s41420-020-0286-z. [PMID] 32566256.
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Molecular carcinogenesis. 58(12):2327-2339 [DOI] 10.1002/mc.23121. [PMID] 31544312.
Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma.
Oncotarget. 10(55):5671-5679 [DOI] 10.18632/oncotarget.27144. [PMID] 31620242.
Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.
The oncologist. 24(7):989-996 [DOI] 10.1634/theoncologist.2019-0047. [PMID] 31019022.
Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma.
JAMA network open. 2(10) [DOI] 10.1001/jamanetworkopen.2019.12416. [PMID] 31577358.
BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
The oncologist. 24(7):973-979 [DOI] 10.1634/theoncologist.2018-0448. [PMID] 30541756.
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
The Annals of pharmacotherapy. 52(5):439-445 [DOI] 10.1177/1060028017749214. [PMID] 29241342.


Post-doctoral Fellowship in Translational Hematology/Oncology
2016-2019 · The Ohio State University
PGY1 Pharmacy Practice Residency
2015-2016 · Baptist Memorial Healthcare – Memphis
2011-2015 · University of South Florida
2007-2011 · University of Central Florida

Teaching Profile

Courses Taught
PHA6136 Clinical Applications of Precision Medicine: Oncology
PHA6935 Selected Topics in Pharmacy

Contact Details

(904) 244-9590